Evaluating the effect of long-term idebenone treatment on respiratory morbidity in patients with Duchenne muscular dystrophy (DMD)
O. Mayer (Philadelphia, United States of America), M. Leinonen (Pratteln, Switzerland), L. Servais (Liege, Belgium), C. Straathof (Leiden, Netherlands), U. Schara (Essen, Germany), T. Voit (London, United Kingdom), E. Mercuri (Rome, Italy), G. Buyse On Behalf Of The Syros Investigators (Leuven, Belgium)
Source: International Congress 2019 – Rare and ultra-rare diseases and the lungs: updates and new perspectives
Disease area: -
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
O. Mayer (Philadelphia, United States of America), M. Leinonen (Pratteln, Switzerland), L. Servais (Liege, Belgium), C. Straathof (Leiden, Netherlands), U. Schara (Essen, Germany), T. Voit (London, United Kingdom), E. Mercuri (Rome, Italy), G. Buyse On Behalf Of The Syros Investigators (Leuven, Belgium). Evaluating the effect of long-term idebenone treatment on respiratory morbidity in patients with Duchenne muscular dystrophy (DMD). 5330
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: